BUST then, cause mister this POS ain't gettin bought out.
This company is more like a Macco shop for customized drugs already out there. Nothing more and nothing less. Paint them up, get FDA approval, and let someone else do the dirty work while they collect peanuts.
Not even sure if the PA drug will even get to market according to the CEO who doesn't know how to keep his words phrased right.
He sounded as confident about the PA drug as BP is about gettin that popped oil gusher plugged at the bottom of the Gulf. Not very.
On top of that he tells shareholders to "ask Astra". Astra's a big cloddy Swiss company that could care less and takes its sweet old time like my pop pop when Mommy tells him its dinner time.
POZN chart looks like my dog Dopey. POS! For the bio-play guys who thought charts don't play into drug approvals, think again. They do. Nothing changes in chart reading. Learn it. Get lessons and let POZN be a big lesson to you.
No buyout will happen. The CEO of this company likes being away from the big cloddy companies like Astra and GSK cause they spend way too much money on their CEOs, VPs and BS like that. Cripes they don't even have descent drug pipelines for as big as they are.
No buyout rumor mongers. Trying to spread a buyout rumor like Dopey always tryin' to hump my leg. Just won't stop cause now that Vimovo is out POZN needs news and those that got stuck holding their wee wee on this stock are desperate to get out. The $25 dollar smilestone won't get much share pop either. This company has screwed its shareholders once again. Poor business plan. Very poor where shareholders are concerned. This companys shares will settle in the low $7s for quite some time.
POS company with no leadership that thinks ahead. Reactive not proactive. Imagine a CC the day after where the CEO basically tell shareholders everything they already knew. Next time save the shreholders time and put a PR out. Typical, and now they rely on Astra. POS!